# Intelligent Bio Solutions Inc. (INBS) · Edgar & Edgarette company card

> Intelligent Bio Solutions (INBS) grew revenue 38.1% in FY2026 to $4 million, operating margin -299% against a 1.2% median for surgical & medical instruments & apparatus, equity 46.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1725430 · fiscal year ended 2026-06-30 · 5 audited years read · [page](https://www.pops4.com/boards/company/INBS) · [JSON](https://www.pops4.com/boards/company/INBS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $4M |
| Revenue growth, 1 year | 38.1% |
| Revenue growth per year | 76.2% |
| Operating margin | -299.1% (prior year -349.8%) |
| Net margin | -295.8% |
| Operating cash flow | −$12M |
| Capital spending | $125,731 |
| Free cash flow | −$12M |
| Cash | $4M |
| Long-term debt | — |
| Total assets | $12M |
| Total equity | $6M |
| Equity ÷ assets | 46.1% |
| Return on equity | -226.3% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -25.5 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Beneish M: -2.33 (below the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -299.1% in FY2026; revenue is hard to predict: its 80% range is ±67%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $4.2M (FY2026). Experience: revenue up 38.1% on the year, up 76.2% a year over 4 years; operating margin -299.1%, up from -349.8%. Soundness: equity 46.1% of assets, return on equity -226.3%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $2.7M and $13.4M next year (method v4.1: its own 4-year record of growth weighed at 50% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $2.4M to $15.0M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -299.1% against a 1.2% median; growth 38.1% against 11.6%.

Range logged 2026-09-24, receipt 9b5da41b20753b2d, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2025-12-16 ([filing](https://www.sec.gov/Archives/edgar/data/1725430/000149315225028003/0001493152-25-028003-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-03-23 ([filing](https://www.sec.gov/Archives/edgar/data/1725430/000149315226012173/0001493152-26-012173-index.htm))

## Recent filings

- DEF 14A · filed 2026-11-02 · [filing](https://www.sec.gov/Archives/edgar/data/1725430/000149315226049613/0001493152-26-049613-index.htm)
- 8-K · filed 2026-10-13 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1725430/000149315226046863/0001493152-26-046863-index.htm)
- 8-K · filed 2026-09-11 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1725430/000149315226042411/0001493152-26-042411-index.htm)
- 8-K · filed 2026-09-09 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1725430/000149315226041901/0001493152-26-041901-index.htm)
- 8-K · filed 2026-09-02 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1725430/000149315226041253/0001493152-26-041253-index.htm)
- 8-K · filed 2026-09-01 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1725430/000149315226041055/0001493152-26-041055-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001725430.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1725430

## Cite

POPS4, Edgar & Edgarette: Intelligent Bio Solutions Inc. (INBS) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/INBS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.